HOME > TOP STORIES
TOP STORIES
-
BUSINESS New Technologies to Cure Cancers, Help Reduce Medical Expenditure: Report
December 21, 2016
-
REGULATORY Four Ministers Map Out Basic Policy for Drug Pricing Revamp
December 21, 2016
-
REGULATORY Basic Policy for Drastic Reform of Drug Pricing System
December 20, 2016
-
BUSINESS Keytruda Gets NSCLC Nod Both in 1st-Line, 2nd-Line Settings
December 20, 2016
-
ACADEMIA New Lung Cancer Guidelines to Give Keytruda Grade A Recommendation as First-Line Treatment
December 19, 2016
-
BUSINESS Fujifilm to Acquire Takeda’s Reagent Unit for 155 Billion Yen
December 16, 2016
-
BUSINESS Nippon Kayaku Introduces “MSLs” to Strengthen Detailing for Oncology Generics, Biosimilars, and Products in Development
December 16, 2016
-
ORGANIZATION JMA Wants Adjustment Rate as High as 5%: Yokokura
December 15, 2016
-
REGULATORY PD-L1 Expression Testing Won’t Be a Must for Opdivo, but Clarification Needed: Chuikyo
December 15, 2016
-
REGULATORY MHLW Drafts Optimal Use Guidelines for Opdivo in NSCLC
December 14, 2016
-
REGULATORY Survey Method, Product Scope for Annual Revisions to Be Discussed in 2017
December 14, 2016
-
BUSINESS Aspen Japan Starting on Right Foot on AG Biz: GSK Japan President
December 13, 2016
-
REGULATORY Chuikyo Reps, Distributors Fret Market Prices Will Be Kept High with Annual Revisions
December 12, 2016
-
REGULATORY (Update) “2%” Adjustment Rate Should Be Made a Discussion Point for Annual Revisions: Chuikyo Rep
December 12, 2016
-
REGULATORY Govt Eyes “Bailout Measures” for Products with Small NHI-Market Price Gaps in Annual Revision Plan
December 9, 2016
-
REGULATORY Shiozaki, Govt Panel Agree on Annual Price Reviews, but Scope of Drugs Still Unclear
December 8, 2016
-
BUSINESS Mitsubishi Tanabe Fending Off Inroads from Biosimilars through Add’l Indications for Remicade
December 8, 2016
-
REGULATORY LDP Tax Panel OKs Refit of R&D Tax Credit System in FY2017
December 7, 2016
-
BUSINESS Acquisition of Long-Listed Drugs to Promote Generic Sales; Sales Target of 50 Billion Yen “in Range”: Kyowa Pharm
December 7, 2016
-
ORGANIZATION Drug Pricing Policy Can’t Be Defined in 2-3 Weeks: PhRMA Exec
December 6, 2016
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
